Clinical Trial Update: Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TT Field therapy with nivolumab and ipilimumab for melanoma with brain metastasis was terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma with Brain Metastasis

Drugs mentioned

• OPTUNE
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Melanoma With Brain Metastasis | Phase 2 | Status: TERMINATED | Results posted: 2022-05-12